DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
...poglycemia in diabetes patients. The
patent grants diobex
exclusive rights to methods of reducing the risk o...s.
In addition to the recently issued U.S. patent, diobex
owns seven U.S.
patent applications and 30 corresp...g foreign patent applications
relating to DIO-901. diobex
also owns or has exclusively licensed seven
DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
under evaluation for DIO-902, diobex
is well positioned to move a strong
pipeline of pr...d more effective than
racemic ketoconazole. About diobex
DiObex, Inc. is a San Francisco-based biotechnolo... products for the treatment of metabolic diseases. diobex
two product candidates in Phase 2 clinical dev...
Diobex Announces Successful Completion of Phase 2a Trial Of
DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes
...citing new drug category," commented Daniel
"DIO-902 offers the possibility of ad..., M.D.,
Vice President of Development at DiObex.
plans on initiating a 16-week phase 2b dose-ranging study
with DIO- 902 in mid 2007.
DiObex, Inc. is a San Francisco-based biopharmac...
DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of
Improved Glycemic Control and Significant Reductions of
LDL-Cholesterol and C-Reactive Protein
...ations normalized during the two week
will conduct a multi-center, 16-week, phase 2b
dos...g patients in three countries in mid-2007.
DiObex, Inc. is a San Francisco-based biopharmac... products for the treatment of metabolic
has two products preparing to enter Phase 2b
DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
...2 is an oral, single enantiomer of ketoconazole, a common
anti-fungal drug. diobex
is developing DIO-902 as a novel cortisol
inhibitor for treating type 2 dia...logy company developing novel
products for diabetes and metabolic diseases. diobex
has two product
candidates in four mid-stage clinical development programs....
DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology
...ANCISCO and LUND, Sweden, March 18 /PRNewswire/ -- diobex
Camurus announced today that they have signed ...ality of life to coma and death," said
David Cory, diobex
CEO. "This license agreement and development progr...in-induced
hypoglycemia in patients with diabetes. diobex
has successfully completed
three Phase 1 proof-of-...
DiObex, Inc. to Present at Merrill Lynch Global Healthcare Conference
...te presentation at the upcoming Merrill Lynch & Co, Inc. Global
Pharmaceutical, Biotechnology and Medical Device Conference in New York,
New York. The diobex
presentation will take place on Wednesday, Feb. 6 at
10:20 a.m. at the Grand Hyatt Hotel in the Broadway room.
DiObex, Inc. is a priv...
DiObex Inc. to Present at BIO Mid-America Venture Forum
...y, September 26th at 1:30 p.m. at
the Hyatt Regency Hotel in Room A. About diobex
DiObex, Inc. is a San Francisco-based biotechnology company founded to
develop novel products for the treatment of metabolic diseases. diobex
two product candidates in Phase 2 clinical development. DIO-901 (very l...